IDH1 and central nervous system neoplasm: This highlights RWD‐derived radiomic signatures combined with clinical/genomic data (e.g., IDH status), enabling pre‐surgical malignancy assessment and treatment stratification, addressing the need for non‐invasive precision diagnostics in heterogeneous CNS tumors.